Skip to main content
OpenTrials
Completed

NCT Number: NCT05167305

The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease

Hospital record of the patients of liver disease admitted from April-May 2021 and April-May 2019 will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and the subsequent 30 d and 90 day readmission rate.

Monitoring and assessment: Hospital records of all patients of liver disease needing admission during the April-May 2019 and 2021, but without active COVID-19 infection, will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and 30 d and 90 d readmission rate.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Diseases Digestive System Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Institute of Liver & Biliary Sciences

New Delhi, National Capital Territory of Delhi, 110070, India

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of liver disease requiring hospital admission

Exclusion criteria

  • Active COVID-19 infection at time of admission or acquiring during hospital stay.

Treatment and study plan

This is an observational study

Other

This is an observational study

Primary outcomes

  1. Comparison of in-hospital mortality rate of patients of liver disease admitted in April-May 2021 and April-May 2019.

    Time frame: Until discharge or death

Secondary outcomes

  1. Comparison of 30 days readmission rate of patients of liver disease.

    Time frame: Day 30

  2. Comparison of 31 to 90 days readmission rate of patients of liver disease.

    Time frame: Day 31-90

  3. Comparison of liver transplantation rates in the two time periods i.e., April-May 2021 and April-May 2019.

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Institute of Liver and Biliary Sciences, India

Other

Registry information

Official study title

The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease-A Record Based Cross-Sectional Study.

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Dec 22, 2021
Registry last updated
Jan 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.